Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: ER-Positive HER2-Negative Breast Cancer
Interventions: DRUG: AZD9833|DRUG: AZD9833 Placebo|DRUG: Anastrozole|DRUG: Anastrozole placebo|DRUG: Letrozole|DRUG: Letrozole placebo|DRUG: Palbociclib|DRUG: Abemaciclib|DRUG: Luteinizing hormone-releasing hormone (LHRH) agonist|DRUG: Ribociclib
Sponsor: AstraZeneca